Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amin...
Main Authors: | Craig A Magaret, David C Benkeser, Brian D Williamson, Bhavesh R Borate, Lindsay N Carpp, Ivelin S Georgiev, Ian Setliff, Adam S Dingens, Noah Simon, Marco Carone, Christopher Simpkins, David Montefiori, Galit Alter, Wen-Han Yu, Michal Juraska, Paul T Edlefsen, Shelly Karuna, Nyaradzo M Mgodi, Srilatha Edugupanti, Peter B Gilbert |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-04-01
|
Series: | PLoS Computational Biology |
Online Access: | http://europepmc.org/articles/PMC6459550?pdf=render |
Similar Items
-
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022-01-01) -
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
by: Yunda Huang, et al.
Published: (2021-02-01) -
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
by: Yunda Huang, et al.
Published: (2023-11-01) -
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionResearch in context
by: Kelly E. Seaton, et al.
Published: (2023-07-01) -
Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)